HOME
Leading the way to a cure

For Researchers

A complete list of Scientific Publications by ALR funded researchers is available here.

Target Identification in Lupus
LETTER OF INTENT DUE DATE: December 23, 2016
APPLICATION DUE DATE: February 17, 2017


The Lupus Research Alliance is pleased to announce that the applications for the Lupus Research Alliance’s Target Identification in Lupus (TIL) grants are now available online. You can access the program guidelines for this application cycle here. The guidelines and application are available through the Altum proposalCENTRAL website at https://proposalcentral.altum.com.

Funding for the TIL award will be made for up to $200,000 per year (for a maximum of three years - total amount up to $600,000) including indirect costs. Funding for the third year is based on the successful submission of a non competitive progress report. The award amount will determined by the Lupus Research Alliance’s Board of Directors based on the results of the peer review process including recommendations from the Lupus Research Alliance’s Scientific Advisory Board.  Detailed guidelines for application and submission are available by clicking on the links listed above.

Deadlines associated with this grant program are as follows:


  • Letter of Intent (LOI):         Due by December 23, 2017

Note: A non-binding letter of intent must be submitted by the investigator in advance of an invitation to apply for a grant. The letter must include a summary of the general theme and the potential future clinical ramification of the project future should it be successful.  Submission of the LOI does not commit the investigator to submitting an application; however it is required to be submitted in order to have access to the full application. The main purpose of this letter is to assist the Lupus Research Alliance’ s Scientific Advisory Board in determining whether the proposed subject matter of the proposal falls within the Lupus Research Alliance’s particular research goals during the upcoming funding year. 


  • Grant Applications:            Due by February 17, 2017

The Lupus Research Alliance funds research that will accelerate the development of new treatments for lupus.  As such, grant proposals should be innovative in direction and utilize state-of-the-art techniques.  Fundamental studies in genetics, immunology, cell biology and molecular biology to identify and characterize molecular systems must be oriented towards the development of drugs that would prevent and/or ameliorate clinical signs and symptoms of lupus. The Lupus Research Alliance particularly welcomes applications proposing research that will apply knowledge gained in other disease areas (e.g., cancer, metabolic diseases) to mechanisms relevant to lupus.

Individuals with doctoral degrees (MD, PhD or equivalent) are eligible to apply.  Scientific independence as evidenced by direction of a research program, a publication record, or other experience that establishes scientific leadership is necessary to apply. The Lupus Research Alliance does not impose geographic restrictions on its applicants, and investigators working anywhere in the world are eligible and encouraged to apply.  The Lupus Research Alliance is willing to appropriately support research in industry or collaborations between academia and industry.

If you have any questions or require any additional information regarding the application process, please contact the Lupus Research Alliance’s Research Administration department at 1-212-218-2840, 1-800-867-1743 or by e-mail at research.admin@lupusresearch.org.

Clinical Trials Request for Posting

Corporations, CRO’s and Investigators if you have clinical trials that you would like the ALR to post information on please click here for more information.

Below you will find links to some Clinical Trials that are looking For Researchers, Patients and to share data.

These trials are in no way affiliated with the ALR and are for informational Purposes only.

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

  • Atacicept is a targeted B-Cell immunomodulator which inhibits APRIL and BLyS effect as well as auto-antibody inhibition. A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE).

Embrace (Efficacy of Belimumab in Lupus Subjects of Black Race)

  • A phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of Belimumab in Adult Subjects of Black Race with Systemic Lupus Erythematosus.

Bliss- SC Belimumab International SLE Study – Subcutaneous

  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously to Subjects with Systemic Lupus Erythematosis (SLE).

Belimumab (Benlysta) Pregnancy Registry - Prospective Cohort Study of Pregnancy Outcomes following Belimumab Exposure

  • The Belimumab Pregnancy Registry is a global, observational cohort study. It will collect prospective pregnancy outcome data on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received belimumab (Benlysta). Infant outcomes from babies born to mothers in this Registry will also be evaluated. Registry data will add to the current clinical experience with belimumab and complement reproductive data from animal toxicology studies. This Registry is sponsored by GlaxoSmithKline (GSK) and managed by Pharmaceutical Product Development (PPD), Inc

Bliss – LN Belimumab International Lupus Nephritis Study

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care Induction and Maintenance Therapy for Active Lupus Nephritis.

PLUTO – (Pediatric Lupus Trial Of belimumab)

  • A Multi-Center, Randomized Parallel Group, Placebo-Controlled Double-Blind trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, A Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients with SLE.

SABLE SLE Registry

  • A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive SLE Treated with or without BENLYSTA (belimumab) (SABLE).

BASE (Belimumab Assessment of Safety in SLE)

  • A Randomized, Double-Blind, Placebo-Controlled 52 Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab.

Last Name

First Name

Degree

Institution

URL

Notes

Crow

Mary

Ph.D

Hospital of Special Surgery

Bio

Co-Chair

Nepom

Gerald T.

M.D. / Ph.D

Benaroya Research Institute at Virginia Mason (BRI)

Bio

Co-Chair

Collins

Mary

M.D.

 

Bio

 

Coyle

Anthony J.

Ph.D

CTI Pfizer Inc.

Bio

 

Fathman

C.Garrison

M.D.

Stanford University

Bio

 

Kalunian

Kenneth

M.D.

University of Californai, San Diego

Bio

 

Kotzin

Brian

M.D.

 

Bio

 

Pascual

Virginia

M.D.

Baylor Institute of Immunology Research

Bio

Pisetsky

David S.

M.D. / Ph.D

Duke University Medical Center

Bio

 

Salmon

Jane

M.D.

Hospital for Special Surgery

Bio

 

Schwartz

Benjamin D.

M.D. / Ph.D

The Camden Group; Washington University School of Medicine

Bio

 

Shlomchik

Mark J.

M.D. / Ph.D

University of Pittsburgh

Bio

 

Tsokos

George

M.D.

Beth Israel Deaconess Medical Center

Bio

 

2016 Alliance for Lupus Research Scientific Calendar

View Our special reports on the ACR and other Meetings

  January 25, 2016 Target Identification Grant Applications Due  
  June 2016 Scientific Advisory Board Meeting  
  April 1, 2016 IFNB ALR/CTI Challenge Grant Applications Due  
  April 29, 2016 Lupus Insight Prize Nominations Due  
  June 23, 2016 Lupus Insight Prize Ceremony  
  October 24-25, 2016 Annual Collaborative Scientific Conference  

Scientific Meetings

February 27- March 1, 2015 4th Annual Meeting of the Lupus Academy – Rome, Italy
March 12-14, 2015 CORA 2015: Controversies in Rheumatology & Autoimmunity – Sorrento, Italy - Happens every two years
May 8-12, 2015 The American Association of Immunologists – IMMUNOLOGY 2015 – New Orleans, Louisiana
June 10-13, 2015 EULAR Congress 2015 – Rome, Italy
June 24- 27, 2015 Federation of Clinical Immunology Societies 2015 – San Diego, California
July 1-4, 2015 Frontiers in Immunology Research International Conference – Algarve, Portugal
August 21-26, 2016 International Congress of Immunology – Melbourne, Australia - Happens every three years
September 2-6, 2015 11th International Congress on Systemic Lupus Erythematosus 2015- Vienna, Austria
September 6-9, 2015 4th European Congress of Immunology- Vienna, Austria
September 6-9, 2015 17th Asia Pacific League of Associations for Rheumatology Congress– Chennai, India
September 21-24, 2015 2015 International Conference on Rheumatic and Autoimmune Diseases (ICRAD 2015)- Shanghai, China
November 1-3,2015  2015 Partnering for Cures- New York, New York
June 8-12, 2016 EULAR Congress 2016 – London, UK

Special Reports

View Highlights from the ALR's 2013 American College of Rheumatology Annual Scientific Meeting

View highlights from the ALR's 2011 American College of Rheumatology Annual Scientific Meeting

View highlights from the ALR's 2010 American College of Rheumatology Annual Scientific Meeting

View the Lupus Congress 2010 Special Report


1.5 million

people in the U.S. have Lupus.

106 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.